Clinical Trial Update: Efficacy and Safety of Two Anti-T-lymphocyte Immune Globulin (ATG-F) Induction Regimens in Anew Kidney Transplant Patients [Phase 4]

View source ↗

Summary

Phase 4 trial comparing two ATG-F induction regimens in de novo kidney transplant recipients completed to assess efficacy and safety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease

Drugs mentioned

• Thymoglobulin (rabbit anti-thymocyte globulin)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: De Novo Kidney Transplant Patients | Phase 4 | Status: COMPLETED